BRIEF-Cogent Biosciences Q3 Income From Operations USD -117.184 Million
Nov 05 (Reuters) - Cogent Biosciences Q3 operating expenses USD 117.184 million.
Related stories
Cogent Biosciences Reports Quarterly Results
Cogent Biosciences reported results for the quarter ended September 30. The available report excerpt contains no figures.
M impact | EQUITY | Nov 05, 2026, 10:27 PM UTC
Cogent Biosciences 3Q 2026: EPS ($0.59) — 10-Q Summary
Cogent Biosciences reported a larger quarterly net loss than a year earlier, as higher research and development spending and commercial-readiness investments lifted operating expen
L impact | EARNINGS | Nov 05, 2026, 09:37 PM UTC
Cogent Biosciences 3Q Loss $111.4M >COGT
L impact | EQUITY | Nov 05, 2026, 09:02 PM UTC
Recordati, CVC acquista 20.000 azioni a 53 euro ciascuna
Recordati, CVC acquista 20.000 azioni a 53 euro ciascuna L’investitore CVC ha acquistato il 5 no
L impact | FX | Nov 05, 2026, 07:01 PM UTC
CVC Buys 20,000 Recordati Shares at EUR 53 Each
CVC Buys 20,000 Recordati Shares at EUR 53 Each CVC Capital Partners bought 20,000 Recordati ord
L impact | FX | Nov 05, 2026, 07:01 PM UTC
US Dollar Nudges Higher Against Loonie as Yields Fall, Oil Jumps
The US dollar edged higher against the Canadian dollar. Bond yields fell and oil prices rose.
M impact | FX | Nov 05, 2026, 06:49 PM UTC